Pay in 4 interest-free payments of $5.52 Learn more
Ships within 48 hours · Estimated delivery Sep 2 - Sep 7
The analysis of 4887 participants treated with tirzepatide and 2,328 participants in the control groups identified 142 participants who developed at least one MACE-4p (inclusive of cardiovascular mortality, myocardial infarction, stroke, and hospitalization for unstable angina) and confirmed the cardiovascular safety with an hazard ratio (HR) of 0.80 (95% CI 0.571.11) for the comparison between tirzepatide and controls
Unaddressed weight and metabolic dysfunction drive a cascade of downstream consequences cardiovascular disease, fatty-liver disease, kidney damage, neuropathy, and shortened lifespan
These effects on energy balance complement incretin-mediated appetite suppression, facilitating greater weight loss
Emerging combination therapies for obesity: Opportunities and challenges
Like all medicines, Wegovy can cause side effects, though not everyone will experience them
Maintaining adequate protein intake, correcting any nutrient deficiencies, and staying consistent with your treatment plan can help support recovery
US$ 28.73
US$ 25.07
US$ 26.61
US$ 25.24
